within Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA29_Sepofarsen;

model Sepofarsen
  extends Pharmacolibrary.Drugs.ATC.S.S01XA29;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01XA29</td></tr><td>route:</td><td>intravitreal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sepofarsen is an antisense oligonucleotide designed to target and restore c.2991+1655A>G splicing defect in the CEP290 gene. It is investigated for the treatment of Leber congenital amaurosis type 10 (LCA10), a rare genetic retinal degenerative disorder. Sepofarsen is not currently approved by regulatory authorities for general use.</p><h4>Pharmacokinetics</h4><p>No human or animal pharmacokinetic parameter data are available in publications for sepofarsen, including standard references, clinicaltrials reporting, and regulatory documents as of mid-2024. Sepofarsen is administered as an intravitreal injection to the eye, where absorption and distribution are mainly local. Systemic exposure is typically negligible for intravitreal oligonucleotide drugs.</p><h4>References</h4><ol><li><p>Russell, SR, Drack, AV, Cideciyan, AV, Jacobson, SG, Leroy, BP, Van Cauwenbergh, C, Ho, AC, Dumitrescu, AV, Han, IC, Martin, M, Pfeifer, WL, Sohn, EH, Walshire, J, Garafalo, AV, Krishnan, AK, Powers, CA, Sumaroka, A, Roman, AJ, Vanhonsebrouck, E, …, &amp; Girach, A (2022). Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial. <i>Nature medicine</i> 28(5) 1014–1021. DOI:<a href=&quot;https://doi.org/10.1038/s41591-022-01755-w&quot;>10.1038/s41591-022-01755-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35379979/&quot;>https://pubmed.ncbi.nlm.nih.gov/35379979</a></p></li><li><p>Xue, K, &amp; MacLaren, RE (2020). Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. <i>Expert opinion on investigational drugs</i> 29(10) 1163–1170. DOI:<a href=&quot;https://doi.org/10.1080/13543784.2020.1804853&quot;>10.1080/13543784.2020.1804853</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32741234/&quot;>https://pubmed.ncbi.nlm.nih.gov/32741234</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Sepofarsen;
